As the molecular mechanism of β-catenin deregulation is not well understood, and stabilized β-catenin is known to translocate into the nucleus and activate genes for proliferation, a novel regulatory factor, hematological and neurological expressed 1 (HN1), for Akt-GSK3β-β-catenin axis is reported here. In our studies, HN1 gene structure was characterized. HN1 expression was found to be epidermal growth factor-responsive in PC-3 cells, and protein expression was also upregulated in PC-3 and LNCaP but not in DU145 cells. Additionally, HN1 was found to be downregulated by the specific AKT inhibitor wortmannin but not with PI3K or MAPK inhibitors, LY294002 and PD98059, respectively, in PC-3 and MCF-7 cells. Further, siRNA-mediated knockdown of HN1 resulted in considerable increase in Akt(S473) and GSK3β(S9),(Y216) phosphorylations; moreover, subsequent accumulation of β-catenin, increase in c-myc expression, and nuclear accumulation of cyclin D1 were observed in PC-3 cells. Knockdown of HN1 also resulted in prolongation of G1 phase in cell cycle, increasing tetraploidy, presumably because of cells escaping from abnormal mitosis in PC-3 cells. Consistently, overexpression of HN1 reversed the cell-cycle–specific observations, resulted in accumulation of cells in G2/M, and reduced the proliferation rate, which were investigated using flow cytometry and methylthiazol tetrazolium assays. As activating mutations of β-catenin have been demonstrated in late-stage tumors, and β-catenin stabilization was correlated with poor prognosis in previous reports, epidermal growth factor-upregulated HN1 expression might have a role in deregulating the AKT-GSK3β(S9)–mediated signaling as a novel compensating mechanism.
Get full access to this article
View all access options for this article.
References
1.
AmanchyR., PeriaswamyB., MathivananS., ReddyR., TattikotaS.G., PandeyA.2007. A curated compendium of phosphorylation motifs. Nat Biotechnol, 25:285–286.
2.
AshiharaK., SaitoT., MizumotoH., NishimuraM., TanakaR., KudoR.2002. Mutation of beta-catenin gene in endometrial cancer but not in associated hyperplasia. Med Electron Microsc, 35:9–15.
3.
BhallaK.N.2003. Microtubule-targeted anticancer agents and apoptosis. Oncogene, 22:9075–9086.
4.
CarthariusK., FrechK., GroteK., KlockeB., HaltmeierM., KlingenhoffA.et al.2005. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics, 21:2933–2942.
5.
Conacci-SorrellM., ZhurinskyJ., Ben-Ze'evA.2002. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest, 109:987–991.
6.
DyrskjotL., KruhofferM., ThykjaerT., MarcussenN., JensenJ.L., MollerK.et al.2004. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res, 64:4040–4048.
FrameS., CohenP.2001. GSK3 takes centre stage more than 20 years after its discovery. Biochem J, 359:1–16.
9.
GotoT., HisatomiO., KotouraM., TokunagaF.2006. Induced expression of hematopoietic- and neurologic-expressed sequence 1 in retinal pigment epithelial cells during newt retina regeneration. Exp Eye Res, 83:972–980.
10.
HajraK.M., FearonE.R.2002. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer, 34:255–268.
11.
HartM.J., de los SantosR., AlbertI.N., RubinfeldB., PolakisP.1998. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol, 8:573–581.
12.
HuangG.M., NgW.L., FarkasJ., HeL., LiangH.A., GordonD.et al.1999. Prostate cancer expression profiling by cDNA sequencing analysis. Genomics, 59:178–186.
13.
HughesK., NikolakakiE., PlyteS.E., TottyN.F., WoodgettJ.R.1993. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J, 12:803–808.
14.
Iacobuzio-DonahueC.A., MaitraA., OlsenM., LoweA.W., van HeekN.T., RostyC.et al.2003. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol, 162:1151–1162.
15.
IharaA., KoizumiH., HashizumeR., UchikoshiT.1996. Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology, 23:1441–1447.
16.
JorissenR.N., WalkerF., PouliotN., GarrettT.P., WardC.W., BurgessA.W.2003. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res, 284:31–53.
17.
KarpovaN., BobinnecY., FouixS., HuitorelP., DebecA.2006. Jupiter, a new Drosophila protein associated with microtubules. Cell Motil Cytoskeleton, 63:301–312.
18.
KishidaS., YamamotoH., IkedaS., KishidaM., SakamotoI., KoyamaS.et al.1998. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J Biol Chem, 273:10823–10826.
19.
KobayashiM., HonmaT., MatsudaY., SuzukiY., NarisawaR., AjiokaY.et al.2000. Nuclear translocation of beta-catenin in colorectal cancer. Br J Cancer, 82:1689–1693.
20.
KorkmazC.G., KorkmazK.S., ManolaJ., XiZ., RisbergB., DanielsenH.et al.2004. Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis. J Urol, 172:1134–1139.
21.
KorkmazK.S., KorkmazC.G., RagnhildstveitE., PretlowT.G., SaatciogluF.2000. An efficient procedure for cloning hormone-responsive genes from a specific tissue. DNA Cell Biol, 19:499–506.
22.
KorkolaJ.E., HouldsworthJ., ChadalavadaR.S., OlshenA.B., DobrzynskiD., ReuterV.E.et al.2006. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res, 66:820–827.
23.
LandiM.T., DrachevaT., RotunnoM., FigueroaJ.D., LiuH., DasguptaA.et al.2008. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One, 3:e1651.
24.
LaughlinK.M., LuoD., LiuC., ShawG., WarringtonK.H.Jr., LawB.K.et al.2009a. Hematopoietic- and neurologic-expressed sequence 1 (Hn1) depletion in B16.F10 melanoma cells promotes a differentiated phenotype that includes increased melanogenesis and cell cycle arrest. Differentiation, 78:35–44.
25.
LaughlinK.M., LuoD., LiuC., ShawG., WarringtonK.H.Jr., QiuJ.et al.2009b. Hematopoietic- and neurologic-expressed sequence 1 expression in the murine GL261 and high-grade human gliomas. Pathol Oncol Res, 15:437–444.
26.
LeeJ., KotliarovaS., KotliarovY., LiA., SuQ., DoninN.M.et al.2006. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell, 9:391–403.
27.
LiuJ., StevensJ., RoteC.A., YostH.J., HuY., NeufeldK.L.et al.2001. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell, 7:927–936.
28.
LuK.H., PattersonA.P., WangL., MarquezR.T., AtkinsonE.N., BaggerlyK.A.et al.2004. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res, 10:3291–3300.
29.
MaruyamaK., OchiaiA., AkimotoS., NakamuraS., BabaS., MoriyaY.et al.2000. Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology, 59:302–309.
30.
NelsonW.J., NusseR.2004. Convergence of Wnt, beta-catenin, and cadherin pathways. Science, 303:1483–1487.
31.
OdajimaT., SasakiY., TanakaN., Kato-MoriY., AsanumaH., IkedaT.et al.2005. Abnormal beta-catenin expression in oral cancer with no gene mutation: correlation with expression of cyclin D1 and epidermal growth factor receptor, Ki-67 labeling index, and clinicopathological features. Hum Pathol, 36:234–241.
32.
OlsenJ.V., BlagoevB., GnadF., MacekB., KumarC., MortensenP.et al.2006. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell, 127:635–648.
33.
PaulS., DeyA.2008. Wnt signaling and cancer development: therapeutic implication. Neoplasma, 55:165–176.
34.
RayasamG.V., TulasiV.K., SodhiR., DavisJ.A., RayA.2009. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol, 156:885–898.
35.
RhodesD.R., YuJ., ShankerK., DeshpandeN., VaramballyR., GhoshD.et al.2004. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia, 6:1–6.
36.
RichardsonA.L., WangZ.C., De NicoloA., LuX., BrownM., MironA.et al.2006. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell, 9:121–132.
37.
RikerA.I., EnkemannS.A., FodstadO., LiuS., RenS., MorrisC.et al.2008. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics, 1:13.
38.
Sanchez-CarbayoM., SocciN.D., LozanoJ., SaintF., Cordon-CardoC.2006. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol, 24:778–789.
39.
StambolicV., WoodgettJ.R.1994. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J, 303,Pt 3:701–704.
40.
SuL.J., ChangC.W., WuY.C., ChenK.C., LinC.J., LiangS.C.et al.2007. Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics, 8:140.
41.
TangW., LaiY.H., HanX.D., WongP.M., PetersL.L., ChuiD.H.1997. Murine Hn1 on chromosome 11 is expressed in hemopoietic and brain tissues. Mamm Genome, 8:695–696.
42.
ThompsonJ.D., HigginsD.G., GibsonT.J.1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res, 22:4673–4680.
43.
ToledoE.M., ColombresM., InestrosaN.C.2008. Wnt signaling in neuroprotection and stem cell differentiation. Prog Neurobiol, 86:281–296.
44.
TomlinsS.A., MehraR., RhodesD.R., CaoX., WangL., DhanasekaranS.M.et al.2007. Integrative molecular concept modeling of prostate cancer progression. Nat Genet, 39:41–51.
45.
TurashviliG., BouchalJ., BaumforthK., WeiW., DziechciarkovaM., EhrmannJ.et al.2007. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer, 7:55.
46.
WangQ.M., FiolC.J., DePaoli-RoachA.A., RoachP.J.1994. Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. J Biol Chem, 269:14566–14574.
47.
YuL.R., ZhuZ., ChanK.C., IssaqH.J., DimitrovD.S., VeenstraT.D.2007. Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra. J Proteome Res, 6:4150–4162.
48.
ZhouG., WangJ., ZhangY., ZhongC., NiJ., WangL.et al.2004. Cloning, expression and subcellular localization of HN1 and HN1L genes, as well as characterization of their orthologs, defining an evolutionarily conserved gene family. Gene, 331:115–123.
49.
ZougmanA., WisniewskiJ.R.2006. Beyond linker histones and high mobility group proteins: global profiling of perchloric acid soluble proteins. J Proteome Res, 5:925–934.
50.
ZujovicV., LuoD., BakerH.V., LopezM.C., MillerK.R., StreitW.J.et al.2005. The facial motor nucleus transcriptional program in response to peripheral nerve injury identifies HN1 as a regeneration-associated gene. J Neurosci Res, 82:581–591.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
